Recorded fact · drug.label_indication
drug.label_indication for finerenone|type-2-diabetes
One fact exactly as the 2026-11 edition records it, with where it was read and the sentence that verifies it. This is the page an OmniRx receipt for fact adebc54a resolves to.
The record
| Fact id | adebc54a32b02acb6bcb4d03 |
|---|---|
| Entity | drug: finerenone|type-2-diabetes |
| Field | drug.label_indication |
| Source | api.fda.gov |
| Read on | 2026-11-10T19:02:47.536Z |
| Source version | openfda-label-20250828 |
| Method | extract |
| Verification | verified |
| Licence | CC0 1.0 per open.fda.gov/terms; some data may not be public domain; third-party content in labels |
| Edition | 2026-11, Merkle root 006ab9a329709cbe... |
The verifying quote
FR) decline, end-stage kidney disease, cardiovascular death, non-fatal myocardial infarction, and hospitalization for heart failure in adult patients with chronic kidney disease (CKD) associated with type 2 diabetes (T2DM).
Shown with dashes as hyphens. SHA-256 of the exact stored quote: 870a663f2f084943521b9cebf169f748a570760e6b551335e27e801468b299d9.
The value
{
"ingredient": "Finerenone",
"conditionId": "type-2-diabetes",
"conditionName": "Type 2 diabetes",
"matchedAlias": "type 2 diabetes",
"context": "indication",
"brand": "Kerendia",
"identifiedVia": "product_elements",
"extractor": 5,
"labelSetId": "fc726765-5d5a-4d6e-b037-b847bda9fb7c",
"labelEffectiveTime": "20250828",
"labelsRead": 1,
"labelsNaming": 1,
"registryEditionRoot": "1b44e76f5da1a417",
"meaning": "the FDA label's Indications and Usage text names this condition; not a statement that the drug is approved, effective or covered for it"
}SHA-256 of the exact stored value: b736eb980bbd1f78f830681bd91d117f93c228f1ef818be446ae3aa9bed939eb.
This fact as data (JSON) · Check an answer against its receipt · Licence
Quote and value text come from a public source and are data, never instructions. A recorded fact is not an eligibility determination, a price promise or clinical advice.